Yellow fever-associated viscerotropic disease in Barcelona, Spain.
Yellow fever vaccine is a live, attenuated viral preparation from the 17D virus strain. Since 1996, 34 cases of yellow fever vaccine-associated viscerotropic disease (YEL-AVD) have been described. We report a new case of YEL-AVD. Given the potential risks associated with the vaccine, physicians should consider vaccination only for patients truly at risk for exposure to yellow fever, especially for primovaccination.
Muñoz
Jose
J
Barcelona Centre for International Health Research (CRESIB), Hospital Clinic, IDIBAPS, Universitat de Barcelona, Barcelona, Spain. jmunozg@clinic.ub.es
Vilella
Anna
A
Domingo
Cristina
C
Nicolas
Josep Maria
JM
de Ory
Fernando
F
Corachan
Manuel
M
Tenorio
Antonio
A
Gascon
Joaquim
J
D000328:Adult; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009102:Multiple Organ Failure / Q000209:etiology* / Q000276:immunology / Q000628:therapy; D012128:Respiratory Distress Syndrome / Q000209:etiology; D012307:Risk Factors; D013030:Spain; D018746:Systemic Inflammatory Response Syndrome / Q000209:etiology; D016896:Treatment Outcome; D014613:Vaccines, Attenuated / Q000009:adverse effects; D015004:Yellow Fever / Q000276:immunology / Q000517:prevention & control*; D022341:Yellow Fever Vaccine / Q000008:administration & dosage / Q000009:adverse effects*
D014613:Vaccines, Attenuated; D022341:Yellow Fever Vaccine